Amneal Pharmaceuticals, Inc.

NasdaqGS:AMRX Stock Report

Market Cap: US$2.3b

Amneal Pharmaceuticals Management

Management criteria checks 3/4

Amneal Pharmaceuticals' CEO is Chirag Patel, appointed in Jan 2005, has a tenure of 20.33 years. total yearly compensation is $7.19M, comprised of 11% salary and 89% bonuses, including company stock and options. directly owns 7.06% of the company’s shares, worth $159.10M. The average tenure of the management team and the board of directors is 5.8 years and 7 years respectively.

Key information

Chirag Patel

Chief executive officer

US$7.2m

Total compensation

CEO salary percentage10.97%
CEO tenure20.3yrs
CEO ownership7.1%
Management average tenure5.8yrs
Board average tenure7yrs

Recent management updates

Recent updates

author-image

CREXONT And Metsera Partnerships Will Capitalize On Growing GLP-1 Market

The strategic collaboration in GLP-1 therapies and biosimilars expands market reach, poised to drive significant future revenue growth.

Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued

Mar 19

There's No Escaping Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Muted Revenues

Feb 17
There's No Escaping Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Muted Revenues

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Nov 10
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success

Jul 10

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Apr 15
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?

Mar 19
Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Dec 28
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company

Dec 10

Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

Nov 28
Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt

Sep 24

Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

Aug 08
Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

Amneal Pharmaceuticals Could Have An Upbeat Q2

Jul 10

These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively

Apr 18
These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively

Amneal Pharmaceuticals: Risk Still Persists

Jan 23

Amneal Pharma reaffirms 2022 guidance

Jan 10

Amneal joins hands with Orion to commercialize generic products in Europe and more countries

Jan 04

Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load

Dec 20
Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load

Amneal Pharmaceuticals large shareholder TPG cuts stake

Dec 14

CEO Compensation Analysis

How has Chirag Patel's remuneration changed compared to Amneal Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$13m

Dec 31 2024US$7mUS$788k

-US$117m

Sep 30 2024n/an/a

-US$184m

Jun 30 2024n/an/a

-US$175m

Mar 31 2024n/an/a

-US$169m

Dec 31 2023US$2mUS$750k

-US$84m

Sep 30 2023n/an/a

US$10m

Jun 30 2023n/an/a

-US$2m

Mar 31 2023n/an/a

-US$135m

Dec 31 2022US$5mUS$750k

-US$130m

Sep 30 2022n/an/a

-US$132m

Jun 30 2022n/an/a

-US$134m

Mar 31 2022n/an/a

US$2m

Dec 31 2021US$5mUS$724k

US$11m

Sep 30 2021n/an/a

US$14m

Jun 30 2021n/an/a

US$9m

Mar 31 2021n/an/a

-US$17m

Dec 31 2020US$2mUS$1

US$91m

Sep 30 2020n/an/a

US$62m

Jun 30 2020n/an/a

-US$194m

Mar 31 2020n/an/a

-US$199m

Dec 31 2019US$446kUS$44k

-US$362m

Sep 30 2019n/an/a

-US$339m

Jun 30 2019n/an/a

-US$67m

Mar 31 2019n/an/a

-US$69m

Dec 31 2018US$325kn/a

-US$21m

Compensation vs Market: Chirag's total compensation ($USD7.19M) is about average for companies of similar size in the US market ($USD6.15M).

Compensation vs Earnings: Chirag's compensation has increased whilst the company is unprofitable.

CEO

Chirag Patel (57 yo)

20.3yrs
Tenure
US$7,187,970
Compensation

Mr. Chirag K. Patel is Co-Founder & Executive Chairman of Kashiv BioSciences, LLC. Mr. Patel has been Co-Chief Executive Officer, President and Director of Amneal Pharmaceuticals, Inc. since August 3, 2019...

Leadership Team

NamePositionTenureCompensationOwnership
Chirag Patel
Co-Founder20.3yrsUS$7.19m7.06%
$ 159.1m
Chintu Patel
Co-Founder23.3yrsUS$7.19m8.17%
$ 184.2m
Anastasios Konidaris
Executive VP & CFO5.2yrsUS$2.85m0.20%
$ 4.5m
Jason Daly
Executive VP3.3yrsUS$2.38m0.010%
$ 234.4k
Nikita Shah
Executive VP & Chief Human Resources Officer11.3yrsUS$2.37m0.12%
$ 2.8m
Andrew Boyer
Executive VP and Chief Commercial Officer of Generics & Biosciences7.3yrsUS$2.79m0.093%
$ 2.1m
Anthony DiMeo
Head of Investor Relationsno datano datano data
Gregory Sgammato
Senior Vice President of Corporate Development2.3yrsno datano data
Pranav Mehta
Senior VP of Strategic Sourcing & Supply Management2.3yrsno datano data
Sanjay Jain
Chief Quality Officer6.3yrsno datano data
Srinivas Kone
Senior VP & Chief Scientific Officer of Generics5.3yrsno datano data
Stanley Fisher
Vice President & Head of Medical Affairsno datano datano data
5.8yrs
Average Tenure
54.5yo
Average Age

Experienced Management: AMRX's management team is seasoned and experienced (5.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Chirag Patel
Co-Founder20.3yrsUS$7.19m7.06%
$ 159.1m
Chintu Patel
Co-Founder23.3yrsUS$7.19m8.17%
$ 184.2m
Paul Meister
Independent Chairman of the Board5.8yrsUS$450.00k0.25%
$ 5.6m
J. Buchi
Independent Director7yrsUS$389.17k0.096%
$ 2.2m
Ted Nark
Independent Director7yrsUS$352.50k0.11%
$ 2.5m
Shlomo Yanai
Independent Director5.4yrsUS$360.00k0.091%
$ 2.1m
Jeffrey George
Independent Director5.4yrsUS$375.00k0.099%
$ 2.2m
Gautam Patel
Director7yrsUS$325.00k0.56%
$ 12.7m
Deborah Autor
Independent Director2.8yrsUS$365.00k0.030%
$ 673.3k
Emily Alva
Independent Director7yrsUS$336.91k0.067%
$ 1.5m
John Kiely
Independent Director5.4yrsUS$380.00k0.082%
$ 1.9m
7.0yrs
Average Tenure
57yo
Average Age

Experienced Board: AMRX's board of directors are considered experienced (7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/23 04:20
End of Day Share Price 2025/05/23 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Amneal Pharmaceuticals, Inc. is covered by 18 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gary NachmanBMO Capital Markets Equity Research
David BuckB. Riley Securities, Inc.
Timothy ChiangBTIG